This article reports the preliminary results of a phase II clinical trial investigating the use of
the estrogen receptor (ER)–targeting PET tracer 4-fluoro-11β-methoxy-16α-18F …

1641 Objectives: 16α-[18F]-fluoro-17β-estradiol (18F-FES) is an estrogen receptor (ER)
ligand and used for the detection of ER-positive malignant tumors such as breast cancer. We …

Background Preoperative accurate assessment of endometrial cancer can assist in the
planning of additional surgical options, and in predicting the prognosis. The aim of the …

Purpose To investigate the correlation between uptake of 16α-[18 F] fluoro-17β-oestradiol
(FES) and expression of oestrogen receptors as well as other related immunohistochemistry …

The grade of histologic differentiation is one of the most important prognostic factors in
patients with endometrial carcinoma and postoperative staging. The aim of this study was to …

In the past few decades, PET with 18 F-FDG has been used for the diagnosis of
gynecological malignancies and is considered to be superior to conventional imaging …

Abstract 16α-[18 F] Fluoro-17β-estradiol (FES) is an estrogen receptor (ER) ligand used for
the detection of ER-positive malignant tumors such as breast cancer. We recently reported …

The aim of this study was to evaluate the diagnostic performance of 18F-FDG PET/CT for the
preoperative assessment of lymph node metastases (LNM) in endometrial cancer patients …

59 Objectives: 4FMFES is a recently developed PET tracer for estrogen receptor (ER)
imaging. The aim of this study was to evaluate the biodistribution, the dosimetry and the …

Purpose To explore the diagnostic value of integrated positron emission
tomography/magnetic resonance imaging (PET/MRI) for the staging of endometrial …